Moderna mRNA vaccine almost halves the risk of skin cancer returning - Nature — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna developed an mRNA vaccine that reduced the risk of skin cancer recurrence by 44% in patients with high-risk melanoma, according to trial data reported in Nature.
- Nature highlighted the vaccine's success in cutting melanoma recurrence, framing it as a major step forward in cancer immunotherapy.
- WSJ noted the trial results did not meet earlier market expectations, tempering enthusiasm despite the clinical benefit.
- Wired reported the 40+ percent reduction in melanoma recurrence, aligning with Nature’s emphasis on the medical significance of the outcome.
- Moderna stock declined further as investors weighed the trial results, reflecting skepticism about the commercial or regulatory impact despite the positive efficacy data.
Why it matters: Patients with high-risk melanoma stand to gain from a vaccine that cuts recurrence by nearly half, but Moderna faces a disconnect between clinical success and market valuation, as investors price in less upside than anticipated from the trial results.
Ask SkimNews
